Sit Investment Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sit Investment Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,500	Closed	-$1.94M	–	544
2024 Q2	$1.94M	Hold	23,500	–	–	0.04%	295
2024 Q1	$2.05M	Hold	23,500	–	–	0.05%	294
2023 Q4	$2.27M	Hold	23,500	–	–	0.06%	287
2023 Q3	$2.08M	Hold	23,500	–	–	0.06%	284
2023 Q2	$2.04M	Hold	23,500	–	–	0.05%	286
2023 Q1	$2.29M	Hold	23,500	–	–	0.06%	279
2022 Q4	$2.43M	Hold	23,500	–	–	0.07%	273
2022 Q3	$1.99M	Hold	23,500	–	–	0.06%	278
2022 Q2	$1.95M	Hold	23,500	–	–	0.06%	280
2022 Q1	$1.81M	Hold	23,500	–	–	0.05%	306
2021 Q4	$2.08M	Hold	23,500	–	–	0.05%	302
2021 Q3	$1.82M	Hold	23,500	–	–	0.05%	307
2021 Q2	$1.96M	Hold	23,500	–	–	0.05%	300
2021 Q1	$1.77M	Hold	23,500	–	–	0.05%	310
2020 Q4	$2.06M	Hold	23,500	–	–	0.06%	287
2020 Q3	$1.79M	Hold	23,500	–	–	0.05%	290
2020 Q2	$2.9M	Hold	23,500	–	–	0.09%	232
2020 Q1	$1.99M	Buy	23,500 +3,200	+16%	+$276K	0.08%	262
2019 Q4	$1.72M	Buy	+20,300	New	+$1.53M	0.05%	306

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Sit Investment Associates's BMRN Position: Q3 2024 in Review

Sit Investment Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 23,500 shares — an estimated $1.94M sold.

Sit Investment Associates first reported a position in BMRN in Q4 2019 and held it in 19 quarters. The position peaked at $2.9M in Q2 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Sit Investment Associates reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Sit Investment Associates sold 23,500 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $1.94M.
Sit Investment Associates first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 19 quarters.
Sit Investment Associates's BioMarin Pharmaceuticals position peaked at $2.9M in Q2 2020.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Sit Investment Associates's 13F filing for Q3 2024, filed 13 Nov 2024.